Delving into the Latest Updates on Motolimod with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Motolimod (USAN/INN)

Target

TLR8

Action

agonists

Mechanism

TLR8 agonists(Toll like receptor 8 agonists)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [1]

Active Indication

Head and Neck NeoplasmsOvarian CancerPeritoneal Neoplasms

Inactive Indication

Advanced cancerAdvanced Malignant Solid NeoplasmB-Cell Lymphoma+ [7]

Originator Organization

Array BioPharma, Inc.

Active Organization

Array BioPharma, Inc.

Inactive Organization

MedImmune LLC

Celgene Corp.

Presage Biosciences, Inc.

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC28H34N4O2

InChIKeyQSPOQCXMGPDIHI-UHFFFAOYSA-N

CAS Registry926927-61-9

This is a multi-center, single arm, open-label, multi-agent, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of motolimod and motolimod combined with nivolumab when administered intratumorally in microdose quantities via the CIVO device in patients with head and neck squamous cell carcinoma (HNSCC). CIVO stands for comparative in vivo oncology.

Start Date15 Oct 2021

Sponsor / Collaborator

Presage Biosciences, Inc.

[+2]

NCT03906526

/ TerminatedPhase 1

A Phase 1b Multicenter Pre-Surgical Study to Evaluate Immune Biomarker Modulation in Response to Motolimod (VTX-2337) in Combination With Nivolumab in Subjects With Resectable Squamous Cell Carcinoma of the Head and Neck (SCCHN)

This is an open label, Phase 1b pre-operative window of opportunity biomarker trial to analyze the combination of intravenous (IV) anti-PD-1 inhibitor, nivolumab, given along with toll-like receptor 8 (TLR 8) agonist motolimod delivered either subcutaneously (SC) or by intratumoral injection (IT) in subjects with squamous cell carcinoma of the head and neck (SCCHN). Subjects with previously untreated, resectable SCCHN, will be recruited onto this trial and will initially undergo pre-treatment diagnostic imaging and biological sample collection. These subjects will undergo pre-operative study treatment for a 3 to 4-week period prior to a scheduled surgical resection.

Start Date03 Jul 2019

Sponsor / Collaborator

Celgene Corp.

NCT02650635

/ TerminatedPhase 1IIT

Phase IB Study Investigating the Tolerability, Immunomodulatory Impacts and, Therapeutic Correlates of the Novel Toll-like Receptor 8 Agonist Motolimod (MOTO) Plus Cyclophosphamide (CTX) Treatment of Advanced Solid Tumors

This phase Ib trial studies the best way of TLR8 Agonist VTX-2337 and cyclophosphamide in treating patients with a solid tumor that has spread from the primary site (place where it started) to other places in the body (metastatic), progressed for a long time (persistent), come back (recurrent), or is growing, spreading, or getting worse (progressed). TLR8 Agonist VTX-2337 may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving TLR8 Agonist VTX-2337 together with cyclophosphamide may be a better treatment for solid tumors.

Start Date05 Feb 2016

Sponsor / Collaborator

Mayo Clinic

[+1]

100 Clinical Results associated with Motolimod

Login to view more data

100 Translational Medicine associated with Motolimod

Login to view more data

100 Patents (Medical) associated with Motolimod

Login to view more data

35

Literatures (Medical) associated with Motolimod

03 May 2024·Rheumatology

TLR8 aggravates skin inflammation and fibrosis by activating skin fibroblasts in systemic sclerosis

Article

Author: Gao, Jian ; Tang, Yulong ; Chen, Yuanyuan ; Xu, Weihong ; Wang, Lei ; He, Qiuyu ; Zhao, Xiansheng ; Kong, Xiangzhen ; Qian, Feng ; Shi, Xiangguang ; Li, Pengcheng ; Ma, Yanyun ; Huang, Yan ; Jiang, Shuai ; Pu, Weilin ; Huang, Delin ; Wang, Jiucun ; Sun, Dayan ; Liu, Qingmei ; Tu, Wenzhen ; Zhao, Yinhuan ; Wu, Wenyu ; Shui, Xiaochuan ; Wu, Fei ; Zhu, Qing

AbstractObjectivesInnate immunity significantly contributes to SSc pathogenesis. TLR8 is an important innate immune mediator that is implicated in autoimmunity and fibrosis. However, the expression, mechanism of action, and pathogenic role of TLR8 in SSc remain unclear. The aim of this study was to explore the roles and underlying mechanisms of TLR8 in SSc.MethodsThe expression of TLR8 was analysed, based on a public dataset, and then verified in skin tissues and skin fibroblasts of SSc patients. The role of TLR8 in inflammation and fibrosis was investigated using a TLR8-overexpression vector, activator (VTX-2337), inhibitor (cu-cpt-8m), and TLR8 siRNA in skin fibroblasts. The pathogenic role of TLR8 in skin inflammation and fibrosis was further validated in a bleomycin (BLM)-induced mouse skin inflammation and fibrosis model.ResultsTLR8 levels were significantly elevated in SSc skin tissues and myofibroblasts, along with significant activation of the TLR8 pathway. In vitro studies showed that overexpression or activation of TLR8 by a recombinant plasmid or VTX-2337 upregulated IL-6, IL-1β, COL I, COL III and α-SMA in skin fibroblasts. Consistently, both TLR8-siRNA and cu-cpt-8m reversed the phenotypes observed in TLR8-activating fibroblasts. Mechanistically, TLR8 induces skin fibrosis and inflammation in a manner dependent on the MAPK, NF-κB and SMAD2/3 pathways. Subcutaneous injection of cu-cpt-8m significantly alleviated BLM-induced skin inflammation and fibrosis in vivo.ConclusionTLR8 might be a promising therapeutic target for improving the treatment strategy for skin inflammation and fibrosis in SSc.

24 Nov 2023·Journal of Biomolecular Structure and Dynamics

Identification of new potent agonists for toll-like receptor 8 by virtual screening methods, molecular dynamics simulation, and MM-GBSA

Article

Author: Sadeghkhani, Farideh ; Hajihassan, Zahra ; Gharaghani, Sajjad

Toll-like receptor 8 (TLR8), as an endosomal transmembrane receptor, plays a crucial role in the innate immune response to neoplasia and viruses. Previous studies have shown that TLR8 agonists e.g. Motolimod can be used to treat patients with last-stage cancer. In this study, in order to find new suitable ligands for TLR8, 16 PBD codes related to TLR8 complexes were collected to design the pharmacophore models using the Pharmit server. Then the PubChem, and ZINC databases were screened by them. Subsequently, the ADME-Tox features of the compounds were detected using FAF-Drugs4 and the selected compounds were docked to TLR8 (PDB: 3w3j). Molecular dynamics simulation was used to compare compounds with the best docking scores, with Motolimod in complex with TLR8. Finally, two compounds were identified, PubChem: 124126919 (A) and PubChem: 18559540 (B), each with advantages over Motolimod. As the RMSD results showed that compound A has very good flexibility, in terms of energy calculated using the MM-GBSA method, complex B and TLR8 showed the lowest energy level compared to the rest of the complexes. These observations suggest that these two compounds could be used as TLR8 agonists with the desired pharmacological features in future experimental studies.Communicated by Ramaswamy H. Sarma.

01 Jul 2023·Biomedicine & Pharmacotherapy

TLR8 agonist Motolimod-induced inflammatory death for treatment of acute myeloid leukemia

Article

Author: Li, Yunlei ; Xie, Xina ; Zhu, Yuqi ; Liu, Linjiang ; Min, Shasha ; Li, Zesong ; Sun, Changqing ; Yang, Wei ; Li, Shi ; Huang, Xiaoru ; Xu, Ying ; Liu, Shuai ; Yan, Jie ; Sun, Xiongfei ; Mao, Longyi ; Zhang, Yu ; Liu, Kaiqing ; Xu, Kui

The clinical treatment of AML is dominated by "7 + 3" therapy, but it often shows great toxicity and limited therapeutic efficacy in application. Therefore, it is urgent to develop novel therapeutic strategies to achieve safe and efficient treatment of AML. Small-molecule inhibitors have the characteristics of high specificity, low off-target toxicity and remarkable therapeutic effect, and are receiving more and more attention in tumor therapy. In this study, we screened a library of 1972 FDA-approved small molecular compounds for those that induced the inflammatory death of AML cells, among which the TLR8 agonist Motolimod (MTL) showed stronger anti-AML activity in the animal model but slight affection on normal lymphocytes in control mice. In terms of mechanism, cellular experiments in AML cell lines proved that TLR8 and LKB1/AMPK are the key distinct mechanisms for MTL triggered caspase-3-dependent cell death and the expression of a large number of inflammatory factors. In conclusion, our findings identified the immunoactivator MTL as a single agent exerting significant anti-AML activity in vitro and in vivo, with strong potential for clinical translation.

100 Deals associated with Motolimod

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10716	Motolimod	-	DB12303

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Head and Neck Neoplasms	Phase 2	-	Array BioPharma, Inc.	-
Ovarian Cancer	Phase 2	-	Array BioPharma, Inc.	-
Peritoneal Neoplasms	Phase 2	-	Array BioPharma, Inc.	-
Recurrent Platinum-Resistant Ovarian Carcinoma	Preclinical	Switzerland	MedImmune LLC	02 Dec 2015
Cutaneous Squamous Cell Carcinoma of the Head and Neck	Preclinical	United States	Celgene Corp.	14 Oct 2013
Fallopian Tube Carcinoma	Preclinical	United States	Celgene Corp.	31 Oct 2012
Ovarian Epithelial Carcinoma	Preclinical	United States	Celgene Corp.	31 Oct 2012
Primary peritoneal carcinoma	Preclinical	United States	Celgene Corp.	31 Oct 2012
Recurrent Primary Peritoneal Carcinoma	Preclinical	United States	Celgene Corp.	31 Oct 2012
B-Cell Lymphoma	Preclinical	United States	Celgene Corp.	01 Jul 2011

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01836029 (Active8, CTgov)	Phase 2	Cutaneous Squamous Cell Carcinoma of the Head and Neck	195	Carboplatin+cisplatin+VTX-2337+5-fluorouracil (Chemotherapy and Cetuximab Plus VTX-2337)	nsdumkyqly(xcliwfjlpb) = ykvgtqrrpk whcoklovas (xccigszqhb, fymqldogpt - bnitstxkin) View more	-	29 Oct 2019
				Placebo+Carboplatin+cisplatin+5-fluorouracil (Chemotherapy and Cetuximab Plus Placebo)	nsdumkyqly(xcliwfjlpb) = jimgdpvtcy whcoklovas (xccigszqhb, oowgqhybmr - wurlghklve) View more
NCT01666444 (Celgene, CTgov)	Phase 2	Primary peritoneal carcinoma \| Recurrent Primary Peritoneal Carcinoma \| Ovarian Epithelial Carcinoma \| Fallopian Tube Carcinoma	297	Placebo+Pegylated Liposomal Doxorubicin (PLD) (Pegylated Liposomal Doxorubicin (PLD) + Placebo)	(twojxbdaxd) = cljtrsyoph cujrduaheq (bixbljdalq, xiigjrcrtr - djmtfyjzgf) View more	-	26 Sep 2019
				Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX) (Pegylated Liposomal Doxorubicin (PLD)+VTX-2337 (VTX))	(twojxbdaxd) = ufoyzbgkqu cujrduaheq (bixbljdalq, uisqzznpmj - pqjqhepctd) View more
NCT02431559 (CTgov)	Phase 1/2	Recurrent Platinum-Resistant Ovarian Carcinoma	53	Pegylated Liposomal Doxorubicin+Durvalumab+Motolimod (Phase 1, Dose Level 0a)	bpawfdjowm(glfushvjnp) = cersynyzvf kslteagmbr (gwkwkgvvfj, djyebytdnl - mnksvrpjks) View more	-	23 Sep 2019
				Pegylated Liposomal Doxorubicin+Durvalumab+Motolimod (Phase 1, Dose Level 0b)	bpawfdjowm(glfushvjnp) = nbwivtsalz kslteagmbr (gwkwkgvvfj, fgsagvmaoi - uqswsiesqk) View more
NCT01836029 (Active8, Pubmed \| JAMA Oncol) Manual	Phase 2	Squamous Cell Carcinoma of Head and Neck	195	Chemotherapy+cetuximab+Motolimod	(pjxmhhlklu) = smnxydzljg lwgbxokmdc (ebmefzbaib ) View more	Negative	01 Nov 2018
				Chemotherapy+cetuximab+Placebo	(pjxmhhlklu) = qfoqphjgqe lwgbxokmdc (ebmefzbaib ) View more
NCT01836029 (Pubmed \| Clin Cancer Res) Manual	Phase 1	Recurrent Squamous Cell Carcinoma of the Head and Neck	13	cetuximab+Motolimod	(rmuiywqrrf) = no protocol-defined dose-limiting toxicities, drug-related deaths, or evidence of synergistic toxicities dhaktamivi (tsuekpcmqu )	Positive	15 May 2017
NCT01666444 (Celgene, Pubmed \| Ann Oncol) Manual	Phase 2	Ovarian Cancer	-	pegylated liposomal doxorubicin+motolimod	(zkggairaws): HR = 1.22, P-Value = 0.923 View more	Positive	01 May 2017
				pegylated liposomal doxorubicin+Placebo
AAAAI2011	Not Applicable	Congestion of nasal mucosa	5	VTX-378 100 μg/dog	(rlalvrmaqx) = wqlcxnxzde ayoqwwapig (pbsepeatmw )	-	01 Feb 2011
				VTX-378 500 μg/dog	(rlalvrmaqx) = jjelpvidzd ayoqwwapig (pbsepeatmw )